HIV/AIDS Therapy

New HIV treatment guides include fosamprenavir calcium for initial antiretroviral treatment

Published in AIDS Weekly, September 11th, 2006

Updated treatment guidelines issued by the International AIDS Society-USA (IAS-USA) now include the HIV protease inhibitor Lexiva boosted with ritonavir as a recommended option for protease inhibitor-based regimens in the initial treatment of adults with HIV infection.

The guidelines were presented at the International AIDS Conference (IAC) in Toronto, Canada.

Lexiva is a protease inhibitor that was co-discovered by GlaxoSmithKline and Vertex Pharmaceuticals Incorporated (VRTX). It is indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults. Lexiva was approved by the U.S. Food and Drug Administration...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2006-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry